Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
guaifenesin + pseudoephedrine + hydrocodone is a fixed-dose combination pharmaceutical product used for the symptomatic relief of cough, nasal congestion, and chest congestion associated with the common cold or influenza. It combines three active ingredients with distinct mechanisms: **guaifenesin**, an expectorant that increases the volume and reduces the viscosity of respiratory tract secretions; **pseudoephedrine**, a sympathomimetic decongestant that stimulates alpha-adrenergic receptors to produce vasoconstriction in the nasal mucosa; and **hydrocodone**, an opioid antitussive that suppresses the cough reflex by acting directly on the cough center in the medulla. Developed by entities such as Shenzhen Pharmaceutical Factory, this combination is typically administered as an oral solution and is indicated for adult patients requiring multi-symptom relief from upper respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guaifenesin + pseudoephedrine + hydrocodone.